{
    "clinical_study": {
        "@rank": "1324", 
        "arm_group": {
            "arm_group_label": "NPB-01", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were\n      confirmed based on the investigators national diagnostic criteria. Patients who meet all\n      inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01\n      (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Subsequently, efficacy\n      of NPB-01 for therapy of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis will be\n      evaluated the disease evaluation score et al.\n\n      As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse\n      events by 20 days after the start of the study treatment."
        }, 
        "brief_title": "Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Stevens-Johnson Syndrome", 
            "Toxic Epidermal Necrolysis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Epidermal Necrolysis, Toxic", 
                "Staphylococcal Scalded Skin Syndrome", 
                "Stevens-Johnson Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients who the disease evaluation score is more than 14 at study medication\n             received.\n\n          2. Patients with corticosteroids over 20mg/day(Prednisolone) at study medication\n             received and continued this treatment more than 2 days.\n\n          3. Patients with treatment effect is insufficiency before study medication received and\n             need additional treatment.\n\n          4. Patients aged more than twenty years old at informed consent.\n\n        Exclusion Criteria:\n\n          1. Patients who the SCORTEN score is more than 4 at study medication received.\n\n          2. Patients with multiple organ failure at study medication received.\n\n          3. Patients with severe respiratory disorder at study medication received.\n\n          4. Patients with Drug-induced hypersensitivity syndrome (DIHS) at informed consent.\n\n          5. Patients with malignancy during treatment at informed consent.\n\n          6. Patients treated with  corticosteroids dosage is change at 2 days before study\n             medication received.\n\n          7. Patients treated with corticosteroids pulse therapy(including semi-pulse therapy) at\n             2 days before study medication received.\n\n          8. Patients treated with plasmapheresis at 2 days before study medication received.\n\n          9. Patients treated with high-dose intravenous immunoglobulin at 28 days before informed\n             consent.\n\n         10. Patients with history of shock or hypersensitivity for NPB-01.\n\n         11. Patients with IgA deficiency.\n\n         12. Patients with severe impaired liver function diagnosed virus hepatitis or cirrhosis\n             et al.\n\n         13. Patients with more than 2mg/dL serum creatinine.\n\n         14. Patients with severe cerebro- or cardiovascular disorders.\n\n         15. Patients with high risk of thromboembolism.\n\n         16. Patients with hemolytic/hemorrhagic anemia.\n\n         17. Patients with severe decreased cardiac function.\n\n         18. Patients with decreased platelet less than 75,000/\u03bcL.."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01696500", 
            "org_study_id": "NPB-01-07/C-01"
        }, 
        "intervention": {
            "arm_group_label": "NPB-01", 
            "intervention_name": "Intravenous immunoglobulin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulins", 
                "Antibodies", 
                "Immunoglobulins, Intravenous", 
                "Rho(D) Immune Globulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "IVIG in Stevens-Johnson syndrome", 
            "Toxic Epidermal Necrolysis", 
            "Patients with Stevens-Johnson syndrome", 
            "Toxic Epidermal Necrolysis unresponsive to corticosteroids"
        ], 
        "lastchanged_date": "October 15, 2013", 
        "location": {
            "contact": {
                "email": "kaihatsu@nihon-pharm.co.jp", 
                "last_name": "Yasumasa Ogawa"
            }, 
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan", 
                    "zip": "101-0031"
                }, 
                "name": "Nihon Pharmaceutical Co., Ltd"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "disease evaluation score", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01696500"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "disease evaluation score", 
                "safety_issue": "No", 
                "time_frame": "4 ,10 ,20 days"
            }, 
            {
                "measure": "avulsed skin area", 
                "safety_issue": "No", 
                "time_frame": "20 days"
            }, 
            {
                "measure": "erythematous area", 
                "safety_issue": "No", 
                "time_frame": "20 days"
            }
        ], 
        "source": "Nihon Pharmaceutical Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nihon Pharmaceutical Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}